Everything below concerns Anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
=== Broadcasters === Robert Siegel (1968), host of All Things Considered on National Public Radio Jim Gardner (1970), anchor for WPVI-TV news in Philadelphia Christopher Kimball (1973), celebrity chef, editor-in-chief of Cook's Illustrated and host of America's Test Kitchen George Whipple III (1977), lawyer and society correspondent for NY1 Pimm Fox (1982), Bloomberg Radio and Bloomberg Television anchorman Fred Katayama (1982), anchor on Reuters Television James Rubin (1982), Sky News anchorman; former assistant secretary of state for public affairs in the Clinton Administration; spokesman for the presidential campaigns of Wesley Clark and John Kerry; husband of Christiane Amanpour George Stephanopoulos (1982), ABC News personality; senior advisor to U.S.
In atherosclerosis, new blood vessels form within plaques, contributing to their growth and instability. These vessels are often fragile, allowing inflammatory cells and fats to enter, which can cause bleeding inside the plaque and increase the risk of rupture. Some studies in animal models suggest that blocking this vessel growth can reduce atherosclerotic progression. In a myocardial infarction, blocked blood flow deprives heart tissue of oxygen, leading to cell damage. Neovascularization in the surrounding area can help restore oxygen supply and limit further injury. Growth factors such as basic fibroblast growth factor (bFGF) and brain natriuretic peptide (BNP) can promote angiogenesis after an acute MI. Following a stroke, ischemic penumbra (the region surrounding the infarct core) can disrupt the cerebral blood flow. Post-stroke angiogenesis in the area helps restore perfusion and supports neurological recovery. Additionally, arteriogenesis contributes to post-stroke blood flow restoration. Various immune cells and cytokines play a role in regulating angiogenesis after ischemic injury.
== Uses == The stilbenoid oxyresveratrol can be isolated from the heartwood of Artocarpus lacucha as well as in Puag Haad, the light brown powder obtained from the aqueous extract of the wood chips of A. lakoocha by boiling, then slow evaporation, followed by cooling. This traditional drug is effective against the intestinal fluke Haplorchis taichui or against taeniasis. Experiments have shown that the heme-peroxidase enzyme from Artocarpus lacucha has the ability to protect against oxidative damage in vitro and possesses wound healing properties. This stable enzyme also has anti-inflammatory properties, making it a potential candidate for use in biotechnological and industrial applications.
Sources: en.wikipedia.org
In 1946, the Atomic Bomb Casualty Commission (ABCC) was established by the National Research Council of the National Academy of Sciences by order of U.S. President Harry S. Truman to study the long-term effects of radiation on survivors of the atomic bombings. In 1975, the ABCC was replaced by the Radiation Effects Research Foundation (RERF). Organizations such as the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), founded in 1955, and the National Academy of Sciences - Advisory Committee on the Biological Effects of Ionizing Radiation (BEIR Committee), founded in 1972, analyze the effects of radiation exposure on humans on the basis of atomic bomb victims who have been examined and, in some cases, medically monitored for decades. They determine the course of the mortality rate as a function of the age of the radiation victims in comparison with the spontaneous rate, and also the dose-dependency of the number of additional deaths. To date, 26 UNSCEAR reports have been published and are available online, most recently in 2017 on the effects of the Fukushima nuclear accident. By 1949, Americans felt increasingly threatened by the possibility of nuclear war with the Soviet Union and sought ways to survive a nuclear attack. The U.S. Federal Civil Defense Administration (USFCDA) was created by the government to educate the public on how to prepare for such an attack. In 1951, with the help of this agency, a children's educational film was produced in the U.S.
The closest relatives within the genus are Ambrosiella xylebori, the symbiont of Xylosandrus compactus (the black twig borer), and Ambrosiella grosmanniae, the symbiont of Xylosandrus germanus (the black stem borer). The genera of Ceratocystidaceae have been revised multiple times based on molecular data, incorporating sequences derived from other Ambrosiella species but not necessarily A. roeperi (and sometimes only including Ambrosiella that have now been moved elsewhere). These analyses imply the genus is most closely related to Huntiella. Within this taxon, studies incorporating the LSU rDNA of A. roeperi suggest that it, A. xylebori, A. hartigii, and A. beaveri comprise a monophyletic lineage excluding A. ferruginea (now Phialoporopsis ferruginea) and most closely aligned to Ceratocystis adiposa, subsequent analysis using 18S rDNA and translation elongation factor alpha confirms this and suggests a monophyletic clade of Ambrosiella associated with the scolytine tribe Xyleborini.
== Research == Along with the clinical trials in obesity that generated the data submitted to regulatory authorities, rimonabant was also studied in clinical trials for diabetes, atherosclerosis, and smoking cessation.
It was proposed, on the basis of these findings, that bicalutamide may act as a SARM for bone remodeling in osteoblasts, different from its antiandrogenic actions in the prostate gland. Likewise, hydroxyflutamide, the active metabolite of the related NSAA flutamide, has been found to inhibit interleukin-6 production in an androgen-responsive osteoblast cell line analogously to androgens, and hence has shown SARM-like activity in bone. In accordance with preclinical findings, bicalutamide monotherapy preserves bone mineral density in men with prostate cancer. Additionally, clinical studies have reported that combined androgen blockade (CAB) with bicalutamide helps to preserve bone parameters to a greater extent than castration monotherapy. It is notable however that in contrast to castration, bicalutamide monotherapy preserves and increases estrogen levels, and estrogens have positive effects both on bone and muscle. This may explain preservation of bone with bicalutamide monotherapy observed in animals and humans. However, it could not explain findings of improved bone parameters with bicalutamide plus castration relative to castration monotherapy, as estrogens are deprived in this context. In terms of muscle, castration and menopause reduce muscle mass in women and men, and in women, estradiol replacement therapy prevents loss of lean body mass. Conversely however, estrogen deficiency did not decrease lean body mass in men treated with a GnRH agonist and testosterone with versus without an aromatase inhibitor.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.